Regional Analysis
Global Induced Pluripotent Stem Cells Market Regional Insights
- North America is expected to be the largest market for induced pluripotent stem cells over the forecast period and it accounted for over 36.3% of the market share in 2024. The growth of the market in North America is due to the presence of leading medical device companies, established healthcare infrastructure, and high healthcare expenditure, have driven market growth over the years.
- Europe is expected to be the second-largest market for induced pluripotent stem cells, which accounted for over 30.4% of the market share in 2024. The growth of the market is due to the presence of several ongoing research initiatives at universities and hospitals across major European countries like Germany, U.K., and France have established standardized protocols for efficiently reprogramming blood cells into iPSCs.
- Asia Pacific is expected to be the fastest-growing market for induced pluripotent stem cells, which is expected to grow at a CAGR of over 12.3% during the forecast period. The growth of the market in Asia Pacific is due to the rapidly developing economies such as China and India, which are expected to showcase high investment opportunities due to increasing healthcare expenditures and expanding healthcare infrastructure. Improving regulatory guidelines and reimbursement policies is positively impacting market dynamics.
Figure 1. Global Induced Pluripotent Stem Cells Market Share (%), By Region, 2024
U.S.: 
U.K. : 
India : 
